The stock gained 16.5% following results that demonstrated encouraging early signs of stabilization and growth, notably from stronger second-half immunoglobulin demand and cost savings exceeding targets, which appear to have alleviated investor concerns about the prior period’s underperformance and cautious outlook.
- Revenue declined 1% to $15.8 billion, and underlying NPAT fell 3% to $2.8 billion, reflecting a reset year rather than a full recovery.
- Immunoglobulin revenue was flat for the full year but grew 7% in the second half, indicating early positive impact from commercial investments in the U.S.
- Seqirus revenue declined 8%, offset by 3% growth in Vifor; seasonal influenza vaccines showed resilience despite sector challenges.
- Transformation program savings of $176 million exceeded expectations, with selective reinvestment ongoing to drive growth.
- Cash flow remained strong at $3.5 billion, supporting a $1 billion share buyback and maintained dividends in USD, underscoring financial stability amid a turnaround phase.
Community Discussion